EZH2 Expression and Response to Neoadjuvant Endocrine Therapy in Estrogen Receptor Positive Invasive Breast Cancer

被引：0
|
作者：
Fineberg, Susan [1 ]
Gan, Yujun [1 ]
机构：
[1] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
来源：
LABORATORY INVESTIGATION | 2022年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
108
引用
收藏
页码：115 / 116
页数：2
相关论文
共 50 条
  • [41] Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
    Inda, Marcia A.
    Blok, Erik J.
    Kuppen, Peter J. K.
    Charehbili, Ayoub
    den Biezen-Timmermans, Eveline C.
    van Brussel, Anne
    Fruytier, Sevgi E.
    Kranenbarg, Elma Meershoek-Klein
    Kloet, Susan
    van der Burg, Bart
    Martens, John W. M.
    Sims, Andrew H.
    Turnbull, Arran K.
    Dixon, J. Michael
    Verhaegh, Wim
    Kroep, Judith R.
    van de Velde, Cornelis J. H.
    van de Stolpe, Anja
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 680 - 689
  • [42] ESTROGEN RECEPTOR IN HUMAN BREAST-CANCER TISSUE AND RESPONSE TO ENDOCRINE THERAPY
    ENGELSMAN, E
    PERSIJN, JP
    KORSTEN, CB
    CLETON, FJ
    BMJ-BRITISH MEDICAL JOURNAL, 1973, 2 (5869): : 750 - 752
  • [43] ASO Visual Abstract: Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer—Comparison of Approaches
    Krislyn N. Miller
    Samantha M. Thomas
    Sydney M. Record
    Laura H. Rosenberger
    Maggie L. DiNome
    Gayle DiLalla
    Jeremy M. Force
    E. Shelley Hwang
    Jennifer K. Plichta
    Annals of Surgical Oncology, 2023, 30 : 6151 - 6151
  • [44] ESTROGEN-RECEPTOR ACTIVITY, PLASMA ESTROGEN CONCENTRATIONS AND RESPONSE TO ENDOCRINE THERAPY IN CANCER OF BREAST
    HAWKINS, RA
    MCFADYEN, I
    KILLEN, E
    ROBERTS, MM
    LANGLANDS, AO
    STEWART, HJ
    HAMILTON, T
    FORREST, APM
    BRITISH JOURNAL OF SURGERY, 1976, 63 (08) : 658 - 659
  • [45] Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer.
    Moore, Halle C. F.
    Maiti, Baidehi
    Rybicki, Lisa A.
    Booth, Christine
    Abraham, Jame
    Budd, G. Thomas
    Andresen, Steven Ware
    Downs-Kelly, Erinn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
    Neupane, Niraj
    Bawek, Sawyer
    Gurusinghe, Sayuri
    Ghaffary, Elham Moases
    Mirmosayyeb, Omid
    Thapa, Sangharsha
    Falkson, Carla
    O'Regan, Ruth
    Dhakal, Ajay
    CANCERS, 2024, 16 (03)
  • [47] Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer
    Haricharan, Svasti
    Schmelz, Jacob
    Schmidt, Cheryl
    Singh, Purba
    Holloway, Kimberly R.
    Anurag, Meenakshi
    Li, Shunqiang
    Kavuri, Shyam M.
    Huang, Shixia
    Edwards, Dean P.
    Suman, Vera
    Hunt, Kelly
    Olson, John A.
    Hoog, Jeremy
    Ma, Cynthia X.
    Bainbridge, Matthew N.
    Ellis, Matthew J.
    CANCER RESEARCH, 2017, 77
  • [48] Inhibition of AKT abrogates resistance to endocrine therapy in estrogen receptor positive breast cancer
    Fox, Emily M.
    Davies, Barry R.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2012, 72
  • [49] Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2520 - +
  • [50] Downregulation of EZH2 is associated with estrogen receptor upregulation and favourable outcome to tamoxifen in advanced breast cancer
    Reijm, E.
    Ruigrok-Ritstier, K.
    van Staveren, I.
    Look, M.
    Meijer-van Gelder, M.
    Sieuwerts, A.
    Sleijfer, S.
    Foekens, J.
    Berns, E.
    Jansen, M.
    EJC SUPPLEMENTS, 2009, 7 (04): : 10 - 10
12345